Robert Drolet, PhD - Publications

Affiliations: 
Merck, Semoy, Centre-Val de Loire, France 

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Rocha EM, De Miranda BR, Castro S, Drolet R, Hatcher NG, Yao L, Smith SM, Keeney MT, Di Maio R, Kofler J, Hastings TG, Greenamyre JT. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease. Neurobiology of Disease. 104626. PMID 31618685 DOI: 10.1016/J.Nbd.2019.104626  0.92
2016 Greshock TJ, Sanders JM, Drolet RE, Rajapakse HA, Chang RK, Kim B, Rada VL, Tiscia HE, Su H, Lai MT, Sur SM, Sanchez RI, Bilodeau MT, Renger JJ, Kern JT, et al. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 27106707 DOI: 10.1016/j.bmcl.2016.04.021  0.92
2015 Usenovic M, Niroomand S, Drolet RE, Yao L, Gaspar RC, Hatcher NG, Schachter J, Renger JJ, Parmentier-Batteur S. Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 14234-50. PMID 26490863 DOI: 10.1523/Jneurosci.1523-15.2015  0.92
2014 Farrell KF, Krishnamachari S, Villanueva E, Lou H, Alerte TN, Peet E, Drolet RE, Perez RG. Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function. Journal of Neurochemistry. 128: 536-46. PMID 24117685 DOI: 10.1111/jnc.12481  0.92
2011 Drolet RE, Sanders JM, Kern JT. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. Journal of Neurogenetics. 25: 140-51. PMID 22077787 DOI: 10.3109/01677063.2011.627072  0.92
2010 Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson's disease. Trends in Pharmacological Sciences. 31: 141-2; author reply . PMID 20096940 DOI: 10.1016/J.Tips.2009.12.006  0.92
2009 Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiology of Disease. 36: 96-102. PMID 19595768 DOI: 10.1016/J.Nbd.2009.06.017  0.92
2009 Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. Neurobiology of Disease. 34: 279-90. PMID 19385059 DOI: 10.1016/J.Nbd.2009.01.016  0.92
2008 Janis KL, Brennan RT, Drolet RE, Behrouz B, Kaufman SK, Lookingland KJ, Goudreau JL. Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease. Journal of Alzheimer's Disease : Jad. 15: 97-107. PMID 18780970 DOI: 10.3233/Jad-2008-15108  0.92
2007 Behrouz B, Drolet RE, Sayed ZA, Lookingland KJ, Goudreau JL. Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult. Neuroscience. 147: 592-8. PMID 17583437 DOI: 10.1016/J.Neuroscience.2007.05.007  0.92
2006 Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2302-12. PMID 17077307 DOI: 10.1096/fj.06-6092com  0.92
2006 Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. Journal of Neurochemistry. 96: 950-9. PMID 16412098 DOI: 10.1111/J.1471-4159.2005.03606.X  0.92
2004 Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology. 25: 761-9. PMID 15288507 DOI: 10.1016/J.Neuro.2004.05.002  0.92
Show low-probability matches.